Presynaptic dopaminergic function in the nucleus accumbens following chronic opiate treatment and precipitated withdrawal

Neurochemical Research

Volumn 24, Issue 1, 1999, Pages 95-107

  Ghosh, Suchandra ^a   Grasing, Kenneth ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Drug dependence; Hippocampus; Morphine; Naloxone; Norepinephrine; Nucleus accumbens; Striatum; Withdrawal syndrome

Indexed keywords

NALOXONE; OPIATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG WITHDRAWAL; GABAERGIC TRANSMISSION; INTERNEURON; MOTOR PERFORMANCE; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; NUCLEUS ACCUMBENS; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM;

ANIMALS; BRAIN; DOPAMINE; DRUG IMPLANTS; HIPPOCAMPUS; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

ANIMALIA;

EID: 0032934025     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020988215732     Document Type: Article

References (64)

1. Fallon J. H. 1988. Topographic organization of ascending dopaminergic projections. Pages 1-9, in Kalivas P. W. and Nemeroff C. B. (eds.), The Mesocorticolimibic Dopamine System, Annals of the New York Academy of Sciences, New York.
2. Rossetti Z. L., Hmaidan Y., and Gessa G. 1992. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Europ. J. Pharm. 221:227-234.
3. Klitenick M. A., DeWitte P., and Kalivas P. W. 1992. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J. Neurochem. 12:2623-2632.
4. Westerink B. H. C., Kwint H. F., and deVries J. B. 1996. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neuroscience 16:2605-2611.
5. Johnson S. W., and North R. A. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurochem. 12:483-488.
6. Cohen G. A., Doze V. A., and Madison D. V. 1992. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron 9:325-335.
7. Sugita S. and North R. A. 1993. Opioid actions on neurons of rat lateral amygdala in vitro. Brain Res. 612:151-155.
8. Kopin I. J. 1994. Neurotransmitters and disorders of the basal ganglia. Pages 899-918, in Siegel G. J., Agranoff B. W., Albers R. W. and Molinoff P. B. (eds.), Basic Neurochemistry, Raven Press, New York.
9. Pozzi L., Trabace L., Invernizzi R., and Samanin R. 1995. Intranigral GR-113808, a selective 5-HT receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res. 692:265-268.
10. Attila L. M. J. and Ahtee L. 1984. Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn-Schmied Arch. Pharm. 327:201-207.
11. Domesick V. B. 1988. Neuroanatomical organization of dopamine neurons in the ventral tegmental area. Pages 10-26, in Kalivas P. W. and Nemeroff C. B. (eds.), The Mesocorticolimibic Dopamine System, Annals of the New York Academy of Sciences, New York.
12. Gorbachvskaya A. I. 1996. Projections of the ventral tegmentum area, formations of the substantia nigra and nuclei of the amygdaloid body on different segments of the caudate nucleus and the accumbens nucleus in dogs. Neurosci. Behav. Physiol. 26:213-219.
13. Tien Ril H. K. G. T., De Vries T. J., Wardeh G., Hogenboom F., Mulder A. H., and Schoffelmeer A. N. M. 1993. Long-lasting reciprocal changes in striatal dopamine and acetylcholine release upon morphine withdrawal. Europ. J. Pharm. 235:321-322.
14. Ghosh S., Patel A. H., Cousins M., and Grasing K. 1998. Different effects of opiate withdrawal on dopamine turnover, uptake, and release in the striatum and nucleus accumbens. Neurochem. Res. 23:877-887.
15. Bosse A. and Kuschinsky K. 1976. Alterations of dopaminergic neurotransmission after chronic morphine treatment: pre- and postjunctional studies in striatal tissue. Naunyn-Schmied. Arch. Pharm. 294:17-22.
16. Stamford J. A. 1995. Voltammetry in brain slices. Pages 65-88, in Schurr A. and Rigor B. M. (eds.), Brain Slices in Basic and Clinical Research, CRC Press, Boca Raton.
17. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R., Chen A. D., Dewey S. L. and Pappas N. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833.
18. Johnson D. W. and Glick S. D. 1994. Handling and/or saline injections alter basal and morphine-evoked changes in dopamine metabolites in the striatum and nucleus accumbens of rats. Pharmacol. Biochem. Behav. 47:765-768.
19. Fraioli F., Moretti C., Paolucci D., Alicicco E., Crescenzi F. and Fortunio G. 1992. Physical exercise stimulates marked concomitant release of beta-endorphin and adrenocorticotropic hormone (ACTH) in peripheral blood in man. Experientia 36:987-989.
20. Abercrombie E. D., Keefe K. A., DiFrischia D. S. and Zigmond M. J. 1989. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 52:1655-1658.
21. Kalivas P. W., Widerlov E., Stanley D., Breese G., and Prange A. J., Jr. 1983. Enkephalin action on the mesolimbic system: a dopamine-dependent and dopamine-independent increase in locomotor activity. J. Pharmacol. Exper. Ther. 227:229-237.
22. Iwamoto E. T. and Way E. L. 1977. Circling behavior and stereotypy induced by intranigral opiate microinjections. J. Pharmacol. Exper. Ther. 203:347-359.
23. Harris G. C. and Aston-Jones G. 1994. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 371:155-157.
24. Grasing K., Bills D., Ghosh S., Schlussman S., Patel A. H. and Woodward J. J. 1997. Opiate modulation of striatal dopamine and hippocampal norepinephrine release following morphine withdrawal. Neurochem. Res. 22:239-248.
25. Rasmussen K., Beitner-Johnson D. B., Krystal J. H., Aghajanian G. K. and Nestler E. J. 1990. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical mechanisms. J. Neurochem. 10:2308-2317.
26. Taylor J. R., Elsworth J. D., Garcia E. J., Grant S. J., Roth R. H. and Redmond D. E. 1988. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology 96: 121-131.
27. Rogawski M. A. and Barker J. L. 1983. Effects of 4-aminopyridine on calcium action potentials and calcium current under voltage clamp in spinal neurons. Brain Res. 280:180-185.
28. Gold L. H., Stinus L., Inturrisi C. E., and Koob G. F. 1994. Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Europ. J. Pharm. 253:45-51.
29. Church W. H., Justice J. B. and Byrd L. D. 1987. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine, and benztropine. Europ. J. Pharm. 139:345-348.
30. Parker E. M. and Cubeddu L. X. 1988. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exper. Ther. 245:199-210.
31. Yoburn B. C., Chen J., Huang T. and Inturrisi C. E. 1985. Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat. J. Pharmacol. Exper. Ther. 235:282-286.
32. Cerletti C., Keinath S. H., Reidenberg M. M. and Adler M. W. 1976. Chronic morphine administration: plasma levels and withdrawal syndrome in rats. Pharmacol. Biochem. Behav. 4:323-327.
33. Rasmussen K. and Aghajanian G. K. 1989. Withdrawal-induced activation of locus coeruleus neurons in opiate dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res. 505:346-350.
34. Laverty R. and Roth R. H. 1980. Clonidine reverses the increased norepinephrine turnover during morphine withdrawal in rats. Brain Res. 182:482-485.
35. Crawley J. N., Laverty R., and Roth R. H. 1979. Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal. Europ. J. Pharm. 57:247-250.
36. Maldonado R. and Koob G. F. 1993. Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Res. 605:128-138.
37. Langer S. Z. and Cavero I. 1980. Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hyperten. 2:372-382.
38. Silverstone P. H., Done C. and Sharp T. 1993. In vivo monoamine release during naloxone precipitated withdrawal. Neuroreport 4: 1043-1045.
39. Done C., Silverstone P. and Sharp T. 1992. Effect of naloxone precipitated morphine withdrawal on noradrenaline release in rat hippocampus in vivo. Europ. J. Pharm. 215:333-336.
40. Silverstone P. H., Done C. and Sharp T. 1992. Clonidine but not nifedipine prevents the release of noradrenaline during naloxone precipitated opiate withdrawal; an in vivo microdialysis study in the rat. Psychopharmacology 109:235-238.
41. Moises H. C., Smith C. B., Spengler R. N. and Hollingsworth P. J. 1986. Presynaptic alpha 2 adrenoreceptor function in dependent rats before and after morphine withdrawal. NIDA Research Monograph 75:579-582.
42. Werling L. L., Brown S. R., and Cox B. M. 1987. Opioid receptor regulation of the release of norpepinephrine in the brain. Neuropharmacology 26:987-996.
43. Ashtee L., Attila L. M. J., Carlson K. R. and Haikala H. 1989. Changes in brain monoaminergic metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state. J. Pharmacol. Exper. Ther. 249:303-310.
44. Blasig J., Gramsch C., Laschka E. and Herz A. 1976. The role of dopamine in withdrawal jumping in morphine dependent rats. Arzneim. Forsch. 26:1104-1106.
45. Gramsch C., Blasig J. and Herz A. 1997. Changes in striatal dopamine metabolism during precipitated morphine withdrawal. Europ. J. Pharm. 44:231-240.
46. Brent P. J. and Chahl L. A. 1991. Effects of naloxone-precipitated withdrawal after a single dose of morphine on catecholamine concentrations in guinea-pig brain. Neurochem. Res. 16:525-531.
47. Tokuyama S. and Ho I. K. 1996. Effects of diltiazem, a calcium channel blocker, on naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Psychopharmacology 125:135-140.
48. Acquas E. and Di Chiara G. 1992. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58:1620-1625.
49. Rossetti Z. L., Melis F., Carboni S. and Gessa G. L. 1992. Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: a common neurochemical substrate for drug dependence. Ann. N. Y. Acad. Sci. 654:513-516.
50. Crippens D. and Robinson T. E. 1994. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis. Brain Res. 650:56-62.
51. Airio J., Attila M., Liekola-Pelho T. and Ahtee L. 1994. Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine. Naunyn-Schmied. Arch. Pharm. 350:548-554.
52. Etemadzadeh E. 1994. Cerebral dopamine and noradrenaline in mice withdrawn from repeated mophine treatment and development of tolerance to a test dose of morphine. Gen. Pharmac. 25: 623-629.
53. Attila L. M. and Ahtee L. 1983. Cerebral dopamine and noradrenaline turnover and effects of morphine test dose in rats withdrawn from 20 days' morphine treatment. Med. Biol. 61:249-257.
54. Etemadzadeh E. 1993. Cerebral catecholamine depletion in mice withdrawn from repeated morphine treatment and development of tolerance to the enhancing effect of morphine on noradrenergic depletion. J. Pharmacol. Exper. Ther. 266:749-755.
55. Ahtee L. and Attila L. M. J. 1987. Cerebral monoamine neurotransmitters in opioid withdrawal and dependence. Med. Biol. 65: 113-119.
56. Tjon G. H. K., De Vries T. J., Ronken E., Hogenboom F., Wardeh G., Mulder A. H., and Schoffelmeer A. N. M. 1994. Repeated and chronic morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its delta and kappa opioid receptor regulation. Europ. J. Pharm. 252:205-212.
57. Pifl C., Drobny H., Reither H., Hornykiewicz O. and Singer E. A. 1995. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharm. 47:368-373.
58. Robertson M. W., Leslie C. A. and Bennett J. P. J. 1991. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res. 538:337-339.
59. Weiss F., Markou A., Lorang M. T. and Koob G. F. 1992. Basal extracellular dopamine levels in the mucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593:314-318.
60. Volkow N. D., Fowler J. S., Wang G. J., Hitzemann R., Logan J., Schlyer D. J., Dewey S. L. and Wolf A. P. 1993. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177.
61. Kuhar M. J. and Pilotte N. S. 1996. Neurochemical changes in cocaine withdrawal. Trends Pharm. Science 17:260-264.
62. Kampman K., Volpicelli J. R., Alterman A., Cornish J., Weinrieb R., Epperson L., Sparkman T. and O'Brien C. P. 1996. Amantadine in the early treatment of cocaine dependence: a double blind, placebo-controlled trial. Drug Alcohol Depend. 41:25-33.
63. Little K. Y., Patel U. N., Clark T. B., and Butts J. D. 1996. Alteration of brain dopamine and serotonin levels in cocaine users: a preliminary report. Am. J. Psychiatry 153:1216-1218.
64. Diana M., Pistis M., Muntoni A., and Gessa G. 1995. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J. Pharmacol. Exper. Ther. 272:781-785.